Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study.
Bottom Line: Human C1-INH concentrate given intravenously (IV) is effective and safe, but venous access may be difficult.We compared SC and IV administration of human pasteurized C1-INH concentrate with respect to pharmacokinetics, pharmacodynamics, and safety.With a relative bioavailability of 39.7%, SC administration of human pasteurized C1-INH yields potentially clinically relevant and sustained plasma levels of C1-INH and is safe and well tolerated.
Affiliation: Hemophilia Center Rhine Main GmbH, Mörfelden-Walldorf, Germany.Show MeSH
Related in: MedlinePlus
Mentions: After IV and SC administration of C1-INH concentrate, the percentage of clHK levels decreased for up to 36 hours (Fig. 4). This was more pronounced with IV administration, where the percentage of clHK decreased from a mean of 46.0% at baseline (0 hr) to 37.1% at 36 hours. In contrast, after SC administration, the lowest value was 42.0%, starting from a baseline value of 44.8%. After 36 hours, the clHK levels increased again to attain approximately baseline levels.
Affiliation: Hemophilia Center Rhine Main GmbH, Mörfelden-Walldorf, Germany.